The current standard treatment of chronic otitic media with cholecteatoma

2015 ◽  
Vol 47 (4) ◽  
pp. 37 ◽  
Author(s):  
Sergey Kosyakov ◽  
Ekaterina Pchelenok
Keyword(s):  
Standard Treatment ◽  
Current Standard ◽  
Current Standard Treatment

scholarly journals Intestinal perforation after radical cystectomy due to drain: Case report

2014 ◽  
Vol 86 (4) ◽  
pp. 295
Author(s):  
Salih Budak ◽  
Hüseyin Aydemir ◽  
Hasan Salih Saglam ◽  
Oztug Adsan
Keyword(s):  
Bladder Cancer ◽  
Case Report ◽  
Radical Cystectomy ◽  
Urinary Diversion ◽  
Potential Risk ◽  
Intestinal Perforation ◽  
Standard Treatment ◽  
Foley Catheter ◽  
Current Standard ◽  
Current Standard Treatment

The current standard treatment for nonmetastatic invasive bladder cancer is radical cystectomy with urinary diversion. Radical cystectomy surgery carries a serious potential risk of complications. In this case report, an intestinal perforation which was thought to be occurred due to a Foley catheter placed as a drain after the cystectomy is presented.

scholarly journals Congenital Pulmonary Alveolar Proteinosis

2013 ◽  
Vol 2013 ◽  
pp. 1-2 ◽  
Author(s):  
Saber Hammami ◽  
Khaled Harrathi ◽  
Khaled Lajmi ◽  
Samir Hadded ◽  
Chebil Ben Meriem ◽  
...  
Keyword(s):  
Pulmonary Surfactant ◽  
Standard Treatment ◽  
Pulmonary Alveolar Proteinosis ◽  
Late Onset ◽  
Spontaneous Remission ◽  
Lung Lavage ◽  
Current Standard ◽  
Whole Lung Lavage ◽  
Current Standard Treatment ◽  
Alveolar Proteinosis

Pulmonary alveolar proteinosis (PAP) is a rare syndrome characterized by pulmonary surfactant accumulation within the alveolar spaces. It occurs with a reported prevalence of 0.1 per 100,000 individuals. Two clinically different pediatric types have been defined as congenital PAP which is fatal and a late-onset PAP which is similar to the adult form and less severe. The clinical course of PAP is variable, ranging from spontaneous remission to respiratory failure. Whole-lung lavage is the current standard treatment for PAP patients. We report a new congenital case of PAP.

scholarly journals Endovascular thrombectomy for the treatment of acute ischemic stroke

2015 ◽  
Vol 74 (1) ◽  
pp. 67-74 ◽  
Author(s):  
Cleusa P. Ferri ◽  
Anna Buehler ◽  
Uri Adrian Prync Flato ◽  
Paulo Puglia Junior ◽  
Jefferson G. Fernandes
Keyword(s):  
Ischemic Stroke ◽  
Acute Ischemic Stroke ◽  
Standard Treatment ◽  
Current Standard ◽  
Clinical Trial Registry ◽  
Endovascular Thrombectomy ◽  
Randomized Controlled ◽  
Current Standard Treatment ◽  
Unknown Status ◽  
New Treatments

ABSTRACT Few patients benefit from the current standard treatment for acute ischemic stroke (AIS), encouraging the development of new treatments. Objective To systematically review the literature on the efficacy and/or safety of endovascular thrombectomy in AIS compared to standard treatment and to identify ongoing randomized controlled trials (RCTs). Method Searches for RCTs were performed in Medline/Embase, and for ongoing trials: International Clinical Trial Registry Platform, Clinicaltrials.gov and ISRCTN registry (to June 15th, 2015). Results From the eight published RCTs, five showed the superiority of treatment that includes thrombectomy compared to standard care alone. From the 13 ongoing RCTs, 3 have been halted, one has not started, one has unknown status and eight will end between 2016 - 2020. Conclusion Evidence favours a combination of the standard therapy with endovascular thrombectomy. The selection criteria however limit the number of people who can benefit. Further studies are needed to prove its cost-effectiveness.

scholarly journals Initial treatment of CLL: integrating biology and functional status

Blood ◽  
2015 ◽  
Vol 126 (4) ◽  
pp. 463-470 ◽  
Author(s):  
Nitin Jain ◽  
Susan O’Brien
Keyword(s):  
Older Patients ◽  
Standard Treatment ◽  
Lymphocytic Leukemia ◽  
First Line ◽  
Current Standard ◽  
Phase 3 ◽  
First Line Therapy ◽  
Line Therapy ◽  
Current Standard Treatment ◽  
Ongoing Phase

Abstract A better understanding of the biology of chronic lymphocytic leukemia (CLL) has led to significant advances in therapeutic strategies for patients with CLL. Chemoimmunotherapy (CIT) has been the standard first-line therapy for CLL. Age and comorbidities can help decide which patients may benefit from a CIT approach. FCR (fludarabine, cyclophosphamide, and rituximab) is the current standard treatment option for younger patients with CLL. For older patients and for patients with renal dysfunction, bendamustine and rituximab may be a better option. For older patients with comorbidities who may not be able to tolerate intensive CIT, the combination treatment of chlorambucil and obinutuzumab or ofatumumab is an option. For patients with del(17p), ibrutinib is the treatment of choice. Several ongoing phase 3 clinical trials with novel therapies will further refine the frontline therapy of CLL.

scholarly journals Novel agents in a young patient with osteosarcoma: A short review

2021 ◽  
Author(s):  
Oskar Steinbrecher ◽  
Thomas Brodowicz ◽  
Wolfgang Lamm
Keyword(s):  
Surgical Resection ◽  
Standard Treatment ◽  
Clinical Course ◽  
Lung Metastases ◽  
Short Review ◽  
Current Standard ◽  
Malignant Bone Tumors ◽  
Isolated Lung ◽  
Current Standard Treatment ◽  
Localized Disease

SummaryOsteosarcomas are rare malignant bone tumors, most frequently occurring in children as well as adolescents and young adults. Therapy of initially localized disease consists of neoadjuvant chemotherapy followed by surgical resection and adjuvant chemotherapy. Osteosarcomas often present relapses, most commonly lung metastases. Treatment of isolated lung metastasis most commonly includes surgical resection. The correct adjuvant treatment option is still under investigation. In this manuscript we describe the clinical course of an osteosarcoma patient and give a review of the literature regarding current standard treatment for localized as well as pulmonary metastatic disease.

scholarly journals Difficulties of Mobilization and Harvesting of Hematopoietic Stem Cells in Heavily Pre-Treated Patients

2017 ◽  
Vol 2 (1) ◽  
pp. 41-44
Author(s):  
Erzsébet Lázár ◽  
Judit-Beáta Köpeczi ◽  
Enikő Kakucs ◽  
István Benedek ◽  
Szende Jakab ◽  
...  
Keyword(s):  
Stem Cells ◽  
Multiple Myeloma ◽  
Stem Cell ◽  
Standard Treatment ◽  
Autologous Transplantation ◽  
Current Standard ◽  
Hematopoietic Stem ◽  
Non Hodgkin Lymphoma ◽  
Key Factor ◽  
Current Standard Treatment

AbstractThis study presents a new method of combined growth factor mobilization with increased dose (15 μg/kg) of filgrastim and standard mono dose of plerixafor in subjects with multiple myeloma, Hodgkin or non-Hodgkin lymphoma. Efficient mobilization is a key factor in the treatment of this group of patients, because autologous transplantation can be performed in cases in which we succeed to obtain a minimally sufficient number of stem cells. Autologous stem cell transplantation is included in the current standard treatment of multiple myeloma and in the relapsed cases of lymphomas.

Sign in / Sign up

Export Citation Format

Share Document